Short answer
Coherus Oncology, Inc. (CHRS) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $14M (up 23.4% year over year) with net income of −$39M.
Q3 2026 key financials · XBRL
- Revenue
- $14M
- +23.4% YoY · −0.2% QoQ
- Net income
- −$39M
- −10.7% YoY · −90.7% QoQ
- Operating margin
- -235.7%
- EPS (diluted)
- −$0.26
- +16.1% YoY · −116.7% QoQ
Source: XBRL data from the Coherus Oncology, Inc. (CHRS) Q3 2026 10-Q on SEC EDGAR. USD.
Coherus Oncology, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $14.3M, up $2.7M YoY from $11.6M, driven by LOQTORZI volume growth
- LOQTORZI best-performing product: revenue $14.0M vs $11.2M YoY
- Gross margin figures not disclosed; operating profitability pressured by $3.4M debt extinguishment loss
- Cash and investments $83.6M vs $172.1M at December 31, 2025; operating cash use $154.0M
- 2026 revenue expected higher, but substantial doubt remains about continuing as a going concern within one year
Risk Factors
- Newly emphasized going-concern risk: $83.6 million liquidity and $1.5 billion accumulated deficit after UDENYCA divestiture
- Commercial risk: LOQTORZI faces penpulimab competition following its April 2025 FDA approval for nasopharyngeal carcinoma
- Regulatory risk: OBBBA Medicaid funding reductions could reduce LOQTORZI sales through lower enrollment and coverage
- Operational risk: U.S. onshoring of LOQTORZI, casdozokitug and tagmokitug manufacturing may face approval delays
- Financial risk: UDENYCA earnouts are uncertain, with $37.5 million payments tied to $300 million and $350 million sales thresholds
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Coherus Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.